Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teduglutide - Takeda

Drug Profile

Teduglutide - Takeda

Alternative Names: ALX-0600; Gattex; Revestive; TAK 633; Teduglutide - Shire

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toronto General Hospital; University of Toronto
  • Developer Shire; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease

Highest Development Phases

  • Marketed Short bowel syndrome
  • Suspended Crohn's disease
  • No development reported Mucositis

Most Recent Events

  • 27 Sep 2023 Takeda completes a phase III trial in Short bowel syndrome (In infants, In children, In adolescents, In adults, In the elderly) in Japan (SC) (NCT05027308)
  • 01 Jun 2022 The National Institute for Health and Care Excellence (NICE) recommends teduglutide, once daily subcutaneous injection, as an option for people living with Short bowel syndrome (SBS) (In infants, In children, In adolescents, In adults, In the elderly) in United Kingdom
  • 24 Jan 2022 Takeda initiates enrolment in a phase III trial for Short bowel syndrome (In infants, In children, In adolescents, In adults, In the elderly) in Japan (SC) (NCT05027308)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top